BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 16061675)

  • 1. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
    Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
    Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
    J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
    Halder J; Kamat AA; Landen CN; Han LY; Lutgendorf SK; Lin YG; Merritt WM; Jennings NB; Chavez-Reyes A; Coleman RL; Gershenson DM; Schmandt R; Cole SW; Lopez-Berestein G; Sood AK
    Clin Cancer Res; 2006 Aug; 12(16):4916-24. PubMed ID: 16914580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.
    Landen CN; Merritt WM; Mangala LS; Sanguino AM; Bucana C; Lu C; Lin YG; Han LY; Kamat AA; Schmandt R; Coleman RL; Gershenson DM; Lopez-Berestein G; Sood AK
    Cancer Biol Ther; 2006 Dec; 5(12):1708-13. PubMed ID: 17106249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained small interfering RNA delivery by mesoporous silicon particles.
    Tanaka T; Mangala LS; Vivas-Mejia PE; Nieves-Alicea R; Mann AP; Mora E; Han HD; Shahzad MM; Liu X; Bhavane R; Gu J; Fakhoury JR; Chiappini C; Lu C; Matsuo K; Godin B; Stone RL; Nick AM; Lopez-Berestein G; Sood AK; Ferrari M
    Cancer Res; 2010 May; 70(9):3687-96. PubMed ID: 20430760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma.
    Guo B; Zhang Y; Luo G; Li L; Zhang J
    Anat Rec (Hoboken); 2009 May; 292(5):633-9. PubMed ID: 19382240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal siRNA for ovarian cancer.
    Mangala LS; Han HD; Lopez-Berestein G; Sood AK
    Methods Mol Biol; 2009; 555():29-42. PubMed ID: 19495686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer.
    Jonson AL; Rogers LM; Ramakrishnan S; Downs LS
    Gynecol Oncol; 2008 Nov; 111(2):356-64. PubMed ID: 18755502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of EphA2 and FAK in ovarian carcinoma.
    Shahzad MM; Lu C; Lee JW; Stone RL; Mitra R; Mangala LS; Lu Y; Baggerly KA; Danes CG; Nick AM; Halder J; Kim HS; Vivas-Mejia P; Landen CN; Lopez-Berestein G; Coleman RL; Sood AK
    Cancer Biol Ther; 2009 Jun; 8(11):1027-34. PubMed ID: 19395869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system.
    Pirollo KF; Rait A; Zhou Q; Hwang SH; Dagata JA; Zon G; Hogrefe RI; Palchik G; Chang EH
    Cancer Res; 2007 Apr; 67(7):2938-43. PubMed ID: 17409398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
    Merritt WM; Lin YG; Spannuth WA; Fletcher MS; Kamat AA; Han LY; Landen CN; Jennings N; De Geest K; Langley RR; Villares G; Sanguino A; Lutgendorf SK; Lopez-Berestein G; Bar-Eli MM; Sood AK
    J Natl Cancer Inst; 2008 Mar; 100(5):359-72. PubMed ID: 18314475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental study of MAT1 gene silencing mediated by siRNA in pancreatic cancer].
    Liu JP; Yuan SZ; Zhang SN
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2719-23. PubMed ID: 18167254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.
    Urban-Klein B; Werth S; Abuharbeid S; Czubayko F; Aigner A
    Gene Ther; 2005 Mar; 12(5):461-6. PubMed ID: 15616603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer.
    Yano J; Hirabayashi K; Nakagawa S; Yamaguchi T; Nogawa M; Kashimori I; Naito H; Kitagawa H; Ishiyama K; Ohgi T; Irimura T
    Clin Cancer Res; 2004 Nov; 10(22):7721-6. PubMed ID: 15570006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
    Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
    Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model.
    Kamlah F; Eul BG; Li S; Lang N; Marsh LM; Seeger W; Grimminger F; Rose F; Hänze J
    Cancer Gene Ther; 2009 Mar; 16(3):195-205. PubMed ID: 18818708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
    Santel A; Aleku M; Keil O; Endruschat J; Esche V; Fisch G; Dames S; Löffler K; Fechtner M; Arnold W; Giese K; Klippel A; Kaufmann J
    Gene Ther; 2006 Aug; 13(16):1222-34. PubMed ID: 16625243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.
    Santel A; Aleku M; Keil O; Endruschat J; Esche V; Durieux B; Löffler K; Fechtner M; Röhl T; Fisch G; Dames S; Arnold W; Giese K; Klippel A; Kaufmann J
    Gene Ther; 2006 Sep; 13(18):1360-70. PubMed ID: 16625242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells.
    Nasreen N; Mohammed KA; Antony VB
    Cancer; 2006 Nov; 107(10):2425-35. PubMed ID: 17041885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics.
    Takei Y; Kadomatsu K; Yuzawa Y; Matsuo S; Muramatsu T
    Cancer Res; 2004 May; 64(10):3365-70. PubMed ID: 15150085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.